Clinical practice. Chronic hepatitis C infection.

@article{Rosen2011ClinicalPC,
  title={Clinical practice. Chronic hepatitis C infection.},
  author={Hugo R. Rosen},
  journal={The New England journal of medicine},
  year={2011},
  volume={364 25},
  pages={
          2429-38
        }
}
  • H. Rosen
  • Published 2011
  • Medicine
  • The New England journal of medicine
This article reviews the evaluation and initial management of chronic hepatitis C infection, with particular attention to the use of new directly acting antiviral agents in treatment regimens. 
Heart Transplantation Outcomes in Patients With Hepatitis C Virus Infection: Potential Impact of Newer Antiviral Treatments After Transplantation.
This study found significant improvements in heart transplant outcomes and survival in patients with hepatitis C virus.
Hepatitis C infection: Updates on treatment guidelines.
TLDR
New treatment guidelines for the evaluation and management of patients with HCV infection are reviewed, offering sustained virologic response rates of over 95%, fewer adverse reactions, and shorter durations of therapy. Expand
Impact of Sofosbuvir‐Based Therapy on Liver Transplant Candidates with Hepatitis C Virus Infection
Sofosbuvir use in patients with decompensated cirrhosis may be associated with reduced liver transplant waitlist mortality and reduced need for transplant.
Systematic review: cost‐effectiveness of direct‐acting antivirals for treatment of hepatitis C genotypes 2‐6
The availability of direct‐acting antivirals (DAAs) has dramatically changed the landscape of hepatitis C virus (HCV) therapy; however, the cost and budget requirements for DAA treatment have beenExpand
Assessment of alcohol histories obtained from patients with liver disease: opportunities to improve early intervention
TLDR
Early assessment and documentation of alcohol consumption is therefore essential, and recommended in both general practice and hospital settings. Expand
Hepatitis C Virus: Gastrointestinal Features
TLDR
Liver failure due to hepatitis C is the most common indication for liver transplantation in the United States, and no vaccine is currently available. Expand
The impact of adherence and an intervention program on patient outcomes and costs in chronic hepatitis C infection
TLDR
The impact of adherence and an intervention program on patient outcomes and costs in chronic hepatitis C infection and the need for further research into this topic is investigated. Expand
Topic Review: Newly FDA Approved Medications for the Treatment of Hepatitis and an Algorithm for Treatment of Hepatitis C Genotype 1
TLDR
This advancement begins a new dawn in the treatment of HCV and provides HCV Genotype1 patients with the greatest opportunity yet to successfully clear the hepatitis C virus. Expand
HIV or human papillomavirus co‐infection among Brazilian individuals infected with hepatitis B and/or hepatitis C
TLDR
To investigate the incidence of co‐infection with HIV and human papillomavirus (HPV) among Brazilian individuals with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, a large number of cases are reported to be connected with HIV. Expand
Morbidity and Mortality Among Community-Based People Who Inject Drugs With a High Hepatitis C and Human Immunodeficiency Virus Burden in Chennai, India
We observed high mortality and liver disease progression associated primarily driven by untreated HIV and chronic hepatitis C as well as alcohol use in a cohort of PWID in India. Interventions toExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 78 REFERENCES
Diagnosis, management, and treatment of hepatitis C: An update
This document has been approved by the AASLD, the Infectious Diseases Society of America, and the American College of Gastroenterology.
Peginterferon and ribavirin for chronic hepatitis C.
A 44-year-old woman with chronic hepatitis C has intermittent fatigue and persistent elevations in serum alanine aminotransferase levels. Treatment with peginterferon and ribavirin is recommended.Expand
A step forward in therapy for hepatitis C.
TLDR
Not until the discovery of the hepatitis C virus (HCV) were the effects of interferon understood; treatment resulted in a decrease in HCV RNA levels, which led to a sustained absence of the virus. Expand
Mixing the right hepatitis C inhibitor cocktail.
TLDR
A review of the first successful Phase III trials of specific targeted antiviral therapy for HCV (STAT-C) compounds, as well as three trials in progress giving the first glimpse of IFN-free combinations of STAT-C agents, looks ahead to the new classes of anti-HCV agents currently in clinical development. Expand
Treatment of chronic hepatitis C in patients with decompensated cirrhosis.
  • G. Everson
  • Medicine
  • Reviews in gastroenterological disorders
  • 2004
TLDR
In the absence of a virologic cure, maintenance therapy with peginterferon may slow disease progression and reduce the rate of clinical decompensation. Expand
Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance.
TLDR
High-risk sexual or iatrogenic exposures may be important contemporary risk factors for HCV infection and the spontaneous viral clearance rate in this contemporary study was similar to that reported for past studies of transfusion-associated HCVs. Expand
EASL Clinical Practice Guidelines: management of hepatitis C virus infection.
TLDR
These EASL CPGs on the management of HCV infection have been updated to include guidance on the use of these two protease inhibitors, and will be updated regularly based on approval of additional new therapies and clinical experience with them. Expand
Natural history of hepatitis C.
Approximately 85% of persons with acute hepatitis C develop chronic hepatitis as determined by persistently abnormal serum enzymes and/or viremia (hepatitis C virus [HCV] RNA). Both the acute andExpand
Interferon for Decreasing the Incidence of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C
TLDR
The incidence of HCC is decreased not only in the patients who respond to interferon completely, accompanied by the loss of HCV RNA from serum, but also in those who obtain normal levels of aminotransferase while HCV persists after interferons. Expand
Natural history of liver fibrosis progression in patients with chronic hepatitis C
TLDR
The host factors of ageing, alcohol consumption, and male sex have a stronger association with fibrosis progression than virological factors in HCV infection. Expand
...
1
2
3
4
5
...